Table 2.
Relationship between treatment response and response of tumor markers.
| Response a | CR | PR | SD | PD | NE | ORR | DCR |
|---|---|---|---|---|---|---|---|
| Total (n = 70) | 6 | 23 | 19 | 15 | 7 | 41.4 % | 68.6 % |
| High-AFP group (AFP ≥ 10ng/mL) | |||||||
| Total (n = 41) | 3 | 11 | 11 | 10 | 6 | 34.2% | 61.0% |
| AFP responder b (n = 19) | 2 | 11 | 3 | 2 | 1 | 68.4%]* | 84.2%]+ |
| AFP non-responder (n = 22) | 1 | 0 | 8 | 8 | 5 | 7.1% | 36.0% |
| High-DCP group (DCP ≥ 40ng/mL) | |||||||
| Total (n = 51) | 4 | 20 | 11 | 12 | 4 | 47.1% | 68.6% |
| DCP responder b (n = 9) | 0 | 6 | 1 | 2 | 0 | 66.7% | 78.8% |
| DCP non-responder (n = 42) | 4 | 14 | 10 | 10 | 4 | 42.9% | 66.7% |
CR, complete response; PR, partial response, SD, stable disease; PD, progressive disease; NE, no evaluation; ORR, objective response rate; DCR, disease control rate; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin. a Evaluated by modified RECIST; ORR = (CR + PR)/(CR + PR + SD + PD + NE); DCR = (CR + PR + SD)/(CR + PR + SD + PD + NE); b AFP and DCP responses were assessed one month after lenvatinib induction; a positive-response was defined as a reduction of ≥40% from baseline; *, p < 0.001; +, p = 0.009.